Haloperidol: Difference between revisions
No edit summary |
No edit summary |
||
| Line 59: | Line 59: | ||
*α1- and α2-adrenergic receptors accounting for lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction | *α1- and α2-adrenergic receptors accounting for lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction | ||
*M1 muscarinic acetylcholine receptors causing anticholinergic symptoms such as dry mouth, blurred vision, constipation, difficulty to urinate, sinus tachycardia, and loss of memory. | *M1 muscarinic acetylcholine receptors causing anticholinergic symptoms such as dry mouth, blurred vision, constipation, difficulty to urinate, sinus tachycardia, and loss of memory. | ||
==Dosage== | |||
{| class="wikitable" | |||
!style="text-align: left"| Indication | |||
!style="text-align: left"| Dose | |||
|- | |||
!style="text-align: left"| | |||
*Schizophrenia | |||
*Psychoses | |||
*Mania | |||
|By ''mouth | |||
ADULT: | |||
*Initially 2 - 20 mg once daily, or | |||
*Initially 2 – 20 mg in divided doses | |||
*Maintenance 1 – 3 mg 3 times a day, adjusted according to response | |||
ELDERLY or debilitated patients: | |||
*Initially 1 – 10 mg once daily, or | |||
*Initially 1 – 10 mg daily in divided doses; | |||
*Maintenance 1 – 3 mg 3 times a day, adjusted according to response | |||
*Maximum 20 mg per day | |||
CHILD 3 to 12 years: | |||
*Initially 500 micrograms daily | |||
*Increased to a usual dose of 1 to 4 mg daily | |||
*Maximum of 6 mg daily | |||
CHILD 13 to 17 years: | |||
*Initially 500 micrograms daily | |||
*Increased to a usual dose of 1 to 6 mg daily | |||
(Maximum of 10 mg daily | |||
By ''intramuscular injection | |||
ADULT: | |||
*2 – 5 mg, repeated dose given according to response and tolerability. | |||
ELDERLY or debilitated patients: | |||
*1 – 2.5 mg, repeated dose given according to response and tolerability. | |||
*Maximum 12 mg per day | |||
|- | |||
!style="text-align: left"| Agitation and restlessness in the elderly | |||
|By ''mouth | |||
ADULT: | |||
*0.75 – 1.5 mg 2-3 times a day, adjusted according to response | |||
|- | |||
!style="text-align: left"| | |||
*Tourette syndrome | |||
*Severe tics | |||
*Intractable hiccup | |||
|By ''mouth | |||
ADULT: | |||
*1.5 – 3 mg 2 -3 times daily | |||
*Maintenance 0.5 – 3 mg 3 times daily | |||
ELDERLY or debilitated patients: | |||
*0.75 – 1.5 mg 2-3 times daily | |||
*Maintenance 0.5 – 1 mg 3 times daily | |||
|- | |||
!style="text-align: left"| Nausea and vomiting of terminal illness | |||
By ''mouth | |||
ADULT: | |||
*1.5 mg 1-2 times daily, increased to | |||
*5 – 10 mg daily in divided doses if necessary | |||
|} | |||
Revision as of 22:29, 18 October 2020
Haloperidol(中文:[[ ]]) is a typical antipsychotic medication. It is used in the treatment of various psychoses including:
- Schizophrenia
- Bipolar disorder
- Delirium
- in Tourette’s syndrome and severe tics
- in intractable hiccups
- in severe anxiety including for sedation of patients in intensive care or palliative care
- in the management of nausea and vomiting of various causes
It may be used by mouth. A long-acting formulation may be used as an injection every 4 weeks in people with schizophrenia, who either forget or refuse to take the medication by mouth. Doses are expressed in terms of the equivalent amount of haloperidol. Haliperidol decanoate 141 mg is equivalent to about 100 mg of haloperiodl. Dosages should be reduced in elderly or debilitated patients; a usual starting dose is half the normal adult dose.
Pronunciation
Haloperidol 1.5mg
Haloperidol 10mg
Haloperidol 1mg
Drug Names
| Generic Name 藥名 | HA Code 藥物代碼 | Classification藥物分類 |
|---|---|---|
| Haloperidol Tab 1 mg | HALO14 | P1S1S3 |
| Haloperidol Tab 1.5 mg | HALO03 | P1S1S3 |
| Haloperidol Tab 5 mg | HALO05 | P1S1S3 |
| Haloperiodl Drops 2mg/ml 30ml | HALO16 | P1S1S3 |
| Haloperidol IM Injection 5mg/ml 1ml | HALO08 | P1S1S3 |
Mechanism of Action
Haloperidol is a typical antipsychotic that blocks dopamine D2 receptor with high affinity. The presumed effectiveness of antipsychotic drugs relied on their ability to block dopamine receptors. This assumption arose from the dopamine hypothesis that maintains that both schizophrenia and bipolar disorder are a result of excessive dopamine activity. In addition, haloperidol also acts as an antagonist (blocking agent) on different postsynaptic and presynaptic receptors:
- Dopamine receptors (subtypes D1, D2, D3, D4 and D5), which account for its antipsychotic properties
- Serotonin receptors (5-HT2, 5-HT6 and 5-HT7), with anxiolytic, antidepressant, and anti-aggressive properties
- Histamine receptors (H1 receptors) accounting for sedation, antiemetic effect
- α1- and α2-adrenergic receptors accounting for lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction
- M1 muscarinic acetylcholine receptors causing anticholinergic symptoms such as dry mouth, blurred vision, constipation, difficulty to urinate, sinus tachycardia, and loss of memory.
Dosage
| Indication | Dose |
|---|---|
|
By mouth
ADULT:
ELDERLY or debilitated patients:
CHILD 3 to 12 years:
CHILD 13 to 17 years:
(Maximum of 10 mg daily By intramuscular injection ADULT:
ELDERLY or debilitated patients:
|
| Agitation and restlessness in the elderly | By mouth
ADULT:
|
|
By mouth
ADULT:
ELDERLY or debilitated patients:
|
| Nausea and vomiting of terminal illness
By mouth ADULT:
|
